Drugs /

allogeneic cd56-positive cd3-negative natural killer cells

Back to Drugs List

Overview

NCI Definition [1]:
A population of allogeneic lymphocytes expressing the CD56 surface antigen and exhibiting a lack of CD3, with immunomodulating activity. Upon infusion of allogeneic CD56-positive CD3-negative natural killer (NK) cells, these cells are able to secrete cytokines and recognize and kill tumor cells as well as virally-infected cells. CD56 is a transmembrane glycoprotein also known as NCAM (Neural Cell Adhesion Molecule).

Clinical Trials

View Clinical Trials for allogeneic cd56-positive cd3-negative natural killer cells

Allogeneic cd56-positive cd3-negative natural killer cells has been investigated in 5 clinical trials, of which 3 are open and 2 are closed. Of the trials investigating allogeneic cd56-positive cd3-negative natural killer cells, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open).

BCR-ABL1 Fusion, Complex karyotype, and DEK-NUP214 Fusion are the most frequent biomarker inclusion criteria for allogeneic cd56-positive cd3-negative natural killer cells clinical trials.

Acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndromes are the most common diseases being investigated in allogeneic cd56-positive cd3-negative natural killer cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating allogeneic cd56-positive cd3-negative natural killer cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
allogeneic cd56-positive cd3-negative natural killer cells, allogeneic cd56+cd3- nk cells
NCIT ID [1]:
C96741

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.